Publications for Christer Sederholm
Co-author map based on ISI articles 2007-

Publications mentioned in social media 6 times*

Keywords

weekly treatment toxicity survival stage radiotherapy patients nsclc non-small median lung gy grade gemcitabine concurrent chemotherapy celecoxib carboplatin cancer advanced

Journal Articles

Christian Dittrich, Zsolt Papai-Szekely, Nuria Vinolas, Christer Sederholm, Joerg T. Hartmann, Dirk Behringer, Gbenga Kazeem, Durisala Desaiah, Monika I. Leschinger and Joachim von Pawel
  A randomised phase II study of pemetrexed versus pemetrexed plus erlotinib as second-line treatment for locally advanced or metastatic non-squamous non-small cell lung cancer
 
Altmetric usage: 5

  European Journal of Cancer, 2014, 50(9), 1571-1580.

Sverre Sörenson, Helena Fohlin, Andrea Lindgren, Magnus Lindskog, Bengt Bergman, Christer Sederholm, Lars Ek, Kristina Lamberg and Birgitta Clinchy
  Predictive role of plasma vascular endothelial growth factor for the effect of celecoxib in advanced non-small cell lung cancer treated with chemotherapy
 
Altmetric usage: 1

  European Journal of Cancer, 2013, 49(1), 115-120.
   Fulltext  PDF  
 Web of Science® Times Cited: 1

Andrea Koch, Bengt Bergman, Erik Holmberg, Christer Sederholm, Lars Ek, Jaroslaw Kosieradzki, Kristina Lamberg, Lars Thaning, Sven-Olof Ydreborg and Sverre Sörenson
  Effect of celecoxib on survival in patients with advanced non-small cell lung cancer: A double blind randomised clinical phase III trial (CYCLUS study) by the Swedish Lung Cancer Study Group
  European Journal of Cancer, 2011, 47(10), 1546-1555.
 Web of Science® Times Cited: 11

Berit M Wennberg, Pia Baumann, Giovanna Gagliardi, Jan Nyman, Ninni Drugge, Morten Hoyer, Anders Traberg, Kristina Nilsson, Elisabeth Morhed, Lars Ekberg, Lena Wittgren, Jo-Asmund Lund, Nina Levin, Christer Sederholm, Rolf Lewensohn and Ingmar Lax
  NTCP modelling of lung toxicity after SBRT comparing the universal survival curve and the linear quadratic model for fractionation correction
  ACTA ONCOLOGICA, 2011, 50(4), 518-527.
 Web of Science® Times Cited: 11

A Hallqvist, G Wagenius, H Rylander, O Brodin, E Holmberg, B Loden, S -B Ewers, S Bergstrom, G Wichardt-Johansson, K Nilsson, L Ekberg, Christer Sederholm and J Nyman
  Concurrent cetuximab and radiotherapy after docetaxel-cisplatin induction chemotherapy in stage III NSCLC: Satellite-A phase II study from the Swedish Lung Cancer Study Group
  LUNG CANCER, 2011, 71(2), 166-172.
 Web of Science® Times Cited: 15

Gunnar Hillerdal, Christer Sederholm and Kerstin Andersson
  Randomized phase II study of gemcitabine and carboplatin +/- sequential docetaxel in non-small cell lung cancer
  LUNG CANCER, 2011, 71(2), 178-181.
 Web of Science® Times Cited: 1

Pia Baumann, Jan Nyman, Morten Hoyer, Berit Wennberg, Giovanna Gagliardi, Ingmar Lax, Ninni Drugge, Lars Ekberg, Signe Friesland, Karl-Axel Johansson, Jo-Asmund Lund, Elisabeth Morhed, Kristina Nilsson, Nina Levin, Merete Paludan, Christer Sederholm, Anders Traberg, Lena Wittgren and Rolf Lewensohn
  Outcome in a Prospective Phase II Trial of Medically Inoperable Stage I Non-Small-Cell Lung Cancer Patients Treated With Stereotactic Body Radiotherapy
  JOURNAL OF CLINICAL ONCOLOGY, 2009, 27(20), 3290-3296.
 Web of Science® Times Cited: 190

J Nyman, S Friesland, A Hallqvist, M Seke, S Bergstrom, L Thaning, B Loden, Christer Sederholm and G Wagenius
  How to improve loco-regional control in stages IIIa-b NSCLC? Results of a three-armed randomized trial from the Swedish Lung Cancer Study Group
  LUNG CANCER, 2009, 65(1), 62-67.
 Web of Science® Times Cited: 8

P. Baumann, J. Nyman, M. Hoyer, G. Gagliardi, I. Lax, B. Wennberg, N. Drugge, L. Ekberg, S. Friesland, K.-A. Johansson, J.-A. Lund, E. Morhed, K. Nilsson, N. Levin, M. Paludan, Christer Sederholm, A. Traberg, L. Wittgren and R. Lewensohn
  Stereotactic body radiotherapy for medically inoperable patients with stage I non-small cell lung cancer - A first report of toxicity related to COPD/CVD in a non-randomized prospective phase II study
  Radiotherapy and Oncology, 2008, 88(3), 359-367.
 Web of Science® Times Cited: 48

Roger Tell, Christer Sederholm, Claes Klintenberg, Lars Franksson, Eva Branden, Gunnar Hillerdal, Ulf Lonn, Carl-Johan Linden, Sven-Borje Ewers, Kristina Lamberg, Eva Mrazek, Britta Loden, Anders Sjogren, Thomas Linne, Signe Friesland and Florin Sirzen
  Multicentre Phase II Trial of Paclitaxel and Carboplatin with Concurrent Radiotherapy in Locally Advanced Non-small Cell Lung Cancer
  Anticancer Research, 2008, 28(5B), 2851-2857.
 Web of Science® Times Cited: 2

Christer Sederholm, G. Hillerdal, K. Lamberg, K. Kolbeck, M. Dufmats, R. Westberg and S.R. Gawande
  Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: The Swedish Lung Cancer Study Group
  Journal of Clinical Oncology, 2005, 23(33), 8380-8388.
 Web of Science® Times Cited: 86

Conference Articles

Jan Nyman, Andreas Hallqvist, Ola Brodin, Kristina Nilsson, Stefan Bergstrom, Britta Loden, Sven-Borje Ewers, Lars Ekberg, Hillevi Rylander, Christer Sederholm and Gunnar Wagenius
  Concurrent cetuximab and radiotherapy after docetaxel-cisplatin induction chemotherapy in stage III NSCLC: a phase II study from the Swedish Lung Cancer Study Group
  in JOURNAL OF THORACIC ONCOLOGY, vol 4, issue 9, 2009.


 Web of Science® Times Cited: 1

* Social media data based on publications from 2011 to present and with a DOI; data delivered by Altmetric.com.